Skip to main content
Clinical Trials/EUCTR2011-004145-41-FR
EUCTR2011-004145-41-FRActive, not recruitingNot Applicable

Efficacy and safety of acebutolol versus propranolol in the proliferative phase of infantile hemangiomas

H Montpellier0 sitesStarted: January 23, 2012Last updated:
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Infant 0 to 6 months
  • hemangioma with the following characteristics: subcutaneous and / or skin, minimum diameter of 1.5 cm for the face and 5 cm outside the face or 3 cm if ulcerated, without functional impairment or requiring treatment with steroid
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 200
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • -indication for a treatment with corticosteroids for an indication other than the hemangioma
  • -indication for a Beta-blocker therapy for an indication other than the hemangioma
  • -any contre indication to the administration of propranolol or acebutolol

Investigators

Sponsor
H Montpellier

Similar Trials

Efficacy and safety of acebutolol versus... | Clinical Trial